Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeFDAFDA Alerts Health Care Providers to Stop New Implants of Certain Ventricular Assist Device System

FDA Alerts Health Care Providers to Stop New Implants of Certain Ventricular Assist Device System

Why It’s Important To Hire A Lawyer Right After Getting Injured

If you are injured, one of the first things you may be thinking is "I need to hire an attorney." You will want to...

What Is Cable Treatment And Why It Is Important

Cables are important. They can be used for many things, such as connecting our laptops to the Internet. However, they are not always given...

Thinking Ahead To 2022 Already? Here’s How You Can Make More Money

If you are reading this article, you may already be thinking of ways how you can make more money. COVID-19: The last couple of years...

6 Medical Equipment You Probably Didn’t Know Existed

The medical field is full of equipment and technology that allows doctors to examine and diagnose patients. While we take much of this technology...

Essential Steps To Get Your Independent Pharmacy Off The Ground

If you just so happen to settle on the lucrative opportunity of starting your own independent pharmacy, then we have listed the essential steps in this article to ensure you can get your business startup off the ground and on the right note.

Medical Tourism

Medical tourism is rapidly gaining popularity nowadays. It provides people who require health care services with an excellent possibility to take advantage of advanced...

Common Car Accident Injuries That You Need to Be Aware Of

You may know someone who has been involved in a car accident or happens to be a victim yourself. While car accident injuries may...

Qualities You Need to Look for When Hiring a Nurse

Nursing is a growing profession, there are approximately three million Registered Nurses(RNs) working in the United States yet the demand for nursing workforce has...

The U.S. Food and Drug Administration is alerting health care providers to no longer implant end-stage heart failure patients with Medtronic’s Heartware Ventricular Assist Device (HVAD) System due to a growing body of observational clinical comparisons that demonstrates a higher frequency of neurological adverse events and mortality associated with the system when compared to other commercially available devices, as well as complaints that the internal pump may delay or fail to restart.

Medtronic is stopping the distribution and sale of the HVAD System and has issued an Urgent Medical Device Communication Notification Letter requesting physicians to stop new implants of the device. This action comes after the company received over 100 complaints involving delay or failure to restart of the HVAD pump, including reports of 14 patient deaths and 13 cases where an explant was necessary. According to Medtronic, there are approximately 2,000 patients in the U.S. implanted with the device and 4,000 worldwide.

The FDA is advising health care providers to follow the instructions provided in the Medtronic Notification Letter, including stopping new implants of the Medtronic HVAD System; using an alternative, such as the Abbott Heartmate 3 Left Ventricular Assist System (LVAS); and advising patients who have the HVAD System to continue normal use of device components and to contact the company for replacement items, such as controllers, batteries, AC/DC adapters and carrying case. In addition, Medtronic’s Notification Letter states that providers should inform patients that elective device explant is not recommended, and decisions about removing the HVAD pump should be made on a case-by-case basis, with careful consideration of the patient’s clinical condition and surgical risks.

“The FDA’s highest priority is patient health and safety. We have been carefully monitoring the adverse events associated with this device and support its removal from the marketplace. The FDA is working closely with both Medtronic and Abbott to ensure patient care is optimized during this transition period and that there is an adequate supply of devices available to provide this patient population with options for end-stage heart failure treatment, said Bram Zuckerman, M.D., director of the Office of Cardiovascular Devices in the FDA’s Center for Devices and Radiological Health. The FDA’s alert is designed to quickly inform health care providers of this critical information so that patients with the current HVAD System continue to receive appropriate care and management. The FDA is committed to facilitating the development of safe and effective devices that can provide patients living with the devastating condition of end-stage heart failure with the opportunity for improved quality of life.

The Medtronic HVAD System was first approved for commercial use in the U.S. in November 2012. It is currently approved as a bridge to heart transplantation in patients who are at risk of death from end-stage left ventricular heart failure, for heart tissue recovery and as destination therapy in patients for whom a heart transplant is not planned. At the time of approval, the HVAD System was compared to another commercially approved left ventricular assist device, and it was determined that the data supported that the probable benefits of the HVAD System outweighed the probable risks. The device is used to treat patients with end-stage heart failure who have not responded to medical management, and the approved HVAD System labeling includes a list of all possible risks associated with the device.

Medtronic’s decision to stop the sale and distribution of the HVAD follows the company’s voluntary recall of a subset of the HVAD pumps in December 2020. The FDA will continue to monitor adverse events associated with the HVAD System and keep health care providers and the public informed as new or additional information becomes available.

The FDA encourages health care professionals and patients to report adverse events or safety problems with the Medtronic HVAD System to FDA’s MedWatch Adverse Event Reporting program.

Additional Resources

spot_img

DON'T MISS

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Under the Program, the FDA will provide the Genio® system with priority review & interaction with FDA’s experts throughout the premarket review phase until the product is commercialized in the US.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy